Home > Insider Trading > Filing (0001144204-14-047406)

Filing Details

Accession Number:: 0001144204-14-047406
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-08-06 17:01:28
Reporting Period:: 2014-08-06

Filing Date:: 2014-08-06
Accepted Time:: 2014-08-06 17:01:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1581720	Loxo Oncology Inc.	LOXO	Pharmaceutical Preparations (2834)	462996673

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055949	D Samuel Isaly	601 Lexington Avenue 54Th Floor New York NY 10022	No	No	Yes	No
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022	No	No	Yes	No
1615374	Orbimed Capital Gp V Llc	601 Lexington Avenue 54Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-08-06	1,562,499	$0.00	1,562,499	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2014-08-06	337,973	$0.00	1,900,472	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2014-08-06	275,385	$13.00	2,175,857	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2014-08-06	1,562,499	$0.00	1,562,499	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2014-08-06	337,973	$0.00	337,973	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Represents shares of Common Stock acquired upon the automatic conversion of Series A Convertible Preferred Stock upon the closing of the Issuer's initial public offering of Common Stock. The shares of Series A Convertible Preferred Stock had no expiration date and were automatically converted into one (1) share of the Issuer's Common Stock, for no additional consideration, at the consummation of the Issuer's initial public offering.
Represents shares of Common Stock acquired upon the automatic conversion of Series B Convertible Preferred Stock upon the closing of the Issuer's initial public offering of Common Stock. The shares of Series B Convertible Preferred Stock had no expiration date and were automatically converted into one (1) share of the Issuer's Common Stock, for no additional consideration, at the consummation of the Issuer's initial public offering.
These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to have beneficial ownership over such securities.
This report on Form 4 is jointly filed by GP V, Advisors, and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently David P. Bonita, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.